Pembrolizumab - Manfaat, Dosis, dan Efek Samping - Alodokter
WEBJan 14, 2024 · Pembrolizumab merupakan obat imunoterapi kanker jenis checkpoint inhibitor. Obat ini tidak membunuh sel kanker secara langsung, tetapi dapat meningkatkan kerja sel darah putih pada sistem imun untuk membunuh sel kanker.
WEBKEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received platinum- containing chemotherapy.
WEBPembrolizumab is a humanised monoclonal anti-programmed cell death-1 (PD-1) antibody (IgG4/kappa isotype with a stabilising sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology.
Obat Imunoterapi Keytruda Bantu Turunkan Risiko Kekambuhan …
WEBFeb 11, 2022 · KOMPAS.com - Sebuah studi global jangka panjang menemukan, obat imunoterapi Keytruda dapat menyelamatkan ribuan nyawa dengan mengurangi risiko kanker payudara agresif. Keytruda, juga dikenal sebagai pembrolizumab, menggunakan sistem kekebalan pasien untuk melawan kanker.
Pembrolizumab - StatPearls - NCBI Bookshelf
WEBJun 26, 2023 · Pembrolizumab is FDA-approved for intravenous use. It comes in either a 50 mg lyophilized powder for reconstitution or a 25 mg/mL solution. The most common administration schedule is a 200 mg infusion given over 30 minutes every three weeks.
Keytruda | European Medicines Agency (EMA)
WEBJul 30, 2015 · The active substance in Keytruda, pembrolizumab, is a monoclonal antibody, a protein that has been designed to recognise and block a receptor (‘target’) called PD-1.
FDA Approval Summary: Pembrolizumab for the treatment of …
WEBSep 9, 2021 · The efficacy of pembrolizumab was supported by the results of whole exome sequencing (WES) analyses of TMB in additional patients enrolled across multiple pembrolizumab clinical trials, and a scientific understanding of …
Pembrolizumab Injection: MedlinePlus Drug Information
WEBPembrolizumab injection is used alone or in combination with other chemotherapy medications to treat certain types of melanoma (a type of skin cancer), Merkel cell carcinoma (MCC; a type of skin cancer), and cutaneous squamous cell …
WEBOne vial contains 100 mg of pembrolizumab in 4 mL of solution. Pembrolizumab is a selective humanized monoclonal antibody designed to block the interaction between PD -1 and its ligands, PD -L1 and PD -L2. Pembrolizumab is an IgG4 kappa immunoglobulin with an approximate molecular weight of 149kDa. Pembrolizumab is
WEBDRUG NAME: Pembrolizumab SYNONYM(S): lambrolizumab1, MK-34752. COMMON TRADE NAME(S): KEYTRUDA® CLASSIFICATION: immunotherapy. Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Pembrolizumab is a selective humanized IgG4 monoclonal antibody known as a programmed cell death 1 (PD-1)